REGENXBIO

226 articles with REGENXBIO

• REGENXBIO to Participate in Upcoming Investor Conferences - March 8, 2023

  3/8/2023

  REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences.

• REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights

  2/28/2023

  REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the fourth quarter and full-year ended December 31, 2022, and recent operational highlights.

• Additional Positive Interim Data from Phase I/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium™

  2/24/2023

  REGENXBIO Inc. (Nasdaq: RGNX) today announced positive interim data from the Phase I/II trial of RGX-111 for the treatment of severe Mucopolysaccharidosis Type I (MPS I).

• Additional Positive Interim Data from Phase I/II/III CAMPSIITE™ Trial of REGENXBIO's RGX-121 for the Treatment of MPS II (Hunter Syndrome) Presented at 19th Annual WORLDSymposiumTM

  2/22/2023

  REGENXBIO Inc. (Nasdaq: RGNX) today announced additional positive interim data from the Phase I/II/III CAMPSIITE™ trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome.

• REGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

  2/21/2023

  REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 28, 2023 , at 4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2022, and recent operational highlights.

• REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium™ 2023

  2/17/2023

  REGENXBIO Inc. announced that three oral and eight poster presentations will be presented at the 19th Annual WORLDSymposium™ 2023, taking place in Orlando, Florida from February 22 through 26, 2023.

• REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process

  2/11/2023

  REGENXBIO Inc. announced results from a Phase II bridging study evaluating the pharmacodynamics, safety and efficacy of RGX-314, a potential one-time therapy delivered subretinally using cGMP material produced by the company's NAVXpress™ bioreactor platform process.

• REGENXBIO Announces Presentation at the Virtual SVB Securities Global Biopharma Conference

  2/8/2023

  REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023.

• REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2023 Conference

  2/6/2023

  REGENXBIO Inc. (Nasdaq: RGNX) today announced that three presentations on RGX-314 will be presented at the Angiogenesis, Exudation, and Degeneration 2023 Conference taking place virtually from February 10-11, 2023.

• REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients

  1/23/2023

  REGENXBIO Inc. (Nasdaq: RGNX) today announced that the Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 for the treatment of Duchenne muscular dystrophy (Duchenne) is now active and recruiting patients.

• Regenxbio Announces Senior Leadership Promotions

  1/9/2023

  REGENXBIO Inc. announced the promotion of Curran Simpson from Chief Technology and Operations Officer to Chief Operating Officer.

• REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023.

• REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease

  12/21/2022

  REGENXBIO Inc. (Nasdaq: RGNX) today announced a comprehensive program update to outline its progress and development plans for RGX-181 and RGX-381.

• REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I

  12/8/2022

  REGENXBIO Inc. (Nasdaq: RGNX) today announced it has completed dosing in the expanded Cohort 2 of the Phase I/II trial of RGX-111 for the treatment of severe Mucopolysaccharidosis Type I (MPS I).

• REGENXBIO to Participate in Upcoming December 2022 Investor Conferences

  11/22/2022

  REGENXBIO Inc. announced it will participate in the following upcoming investor conferences.

• REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

  11/3/2022

  REGENXBIO Inc. announced additional positive interim data from the ongoing Phase II ALTITUDE® trial of RGX-314 for the treatment of diabetic retinopathy without center-involved diabetic macular edema using in-office suprachoroidal delivery.

• REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

  11/3/2022

  REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the third quarter ended September 30, 2022, and recent operational highlights.

• REGENXBIO to Participate in Upcoming November 2022 Investor Conferences

  11/2/2022

  REGENXBIO Inc. announced it will participate in the following upcoming investor conferences.

• REGENXBIO to Host Conference Call on November 3 to Discuss Third Quarter 2022 Financial Results, Recent Operational Highlights and Interim Data from Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy

  10/27/2022

  REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the ALTITUDE ®  clinical trial evaluating RGX-314 using suprachoroidal delivery for the treatment of patients with diabetic retinopathy at the Retina Society 55th Annual Scientific Meeting taking place in Pasadena, CA , from November 2-5, 2022.

• 

  AAO 2022: Janssen, REGENXBIO, Apellis and More

  10/3/2022

  Gene therapies developed by Janssen, Atsena, REGENXBIO and AbbVie showed promise against eye diseases this weekend at the American Academy of Ophthalmology 2022 meeting.